EBS - Emergent Bio is a business reliant on taxpayer dollars: NYT

In an investigative article, the New York Times reveals how Emergent BioSolutions ([[EBS]] -1.2%) profited from selling anthrax vaccines to the government while the pandemic was raging across the country.The paper alleges that the financial interests of a few biotech firms have determined the procurement decisions of the Strategic National Stockpile, the country's emergency reserve for urgently needed medical supplies.‘Chief among them is Emergent BioSolutions,’ the paper notes citing $626M worth government funding the company received last year for the delivery of anthrax vaccines to boost the government supplies in the event of a terrorist attack.At one point, Emergent was identified by the paper as ‘a business heavily dependent on taxpayer dollars’ and ‘an obscure contractor in an obscure corner of the federal bureaucracy.’“The risk of a serious terrorist attack with anthrax is real, but that doesn’t mean you buy unlimited quantities of vaccine,” Dr. Thomas Frieden, a former director of the Centers for

For further details see:

Emergent Bio is a business reliant on taxpayer dollars: NYT